GW Pharma (GWPH) Posts Smaller Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress
February 25, 2020 4:01 PM EST- Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year -
- Total Epidiolex® net product sales of $104.5 million for the fourth quarter and $296.4 million for the first full year of sales -
- Conference call today at 4:30 p.m. ESTÂ -
LONDON and CARLSBAD, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announces financial results for the fourth... More
